Skip to main
BIIB
BIIB logo

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 21%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Biogen is positioned for a positive growth trajectory, as recent product launches like Leqembi, Skyclarys, and Zurzuvae have surpassed consensus expectations, indicating strong commercial execution. Despite expectations of revenue growth not materializing until 2026, management is focused on strategic business development initiatives that are anticipated to drive near-term earnings upside. With projections suggesting that key product launches could generate $2.5 to $3.0 billion in revenue by 2030, Biogen's robust pipeline and ability to address market bottlenecks present significant long-term growth potential.

Bears say

Biogen's reliance on its declining multiple sclerosis franchise, which accounted for 45% of total revenue in 2024, raises concerns about the sustainability of its revenue streams. Additionally, while the company generates substantial income from CD20 collaboration agreements with Roche, contributing 18% of total revenue, the overall dependence on a limited product portfolio can create vulnerability to market fluctuations. Furthermore, with a focus on newer franchises that may not yet have established significant market traction, Biogen's future revenue growth prospects appear uncertain, adding to the negative outlook.

Biogen (BIIB) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 21% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 19 analysts, Biogen (BIIB) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $179.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $179.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.